Literature DB >> 4734384

Alternate complement pathway: factors involved in cobra venom factor (CoVF) activation of the third component of complement (C3).

L G Hunsicker, S Ruddy, K F Austen.   

Abstract

Mesh：

Substances：

Year:  1973        PMID： 4734384

Source DB:  PubMed          Journal:  J Immunol        ISSN： 0022-1767            Impact factor:   5.422


× No keyword cloud information.
  67 in total

1.  Chemotactic activity derived from interaction of factors D and B of the properdin pathway with cobra venom factor or C3B.

Authors:  S Ruddy; K F Austen; E J Goetzl
Journal:  J Clin Invest       Date:  1975-03       Impact factor: 14.808

2.  Complement breakdown products in plasma from patients with systemic lupus erythematosus and patients with membranoproliferative or other glomerulonephritis.

Authors:  L H Perrin; P H Lambert; P A Miescher
Journal:  J Clin Invest       Date:  1975-07       Impact factor: 14.808

3.  Regulation of C5 convertase activity by properdin, factors B and H.

Authors:  J M Weiler
Journal:  Immunol Res       Date:  1989       Impact factor: 2.829

4.  Restoration by purified C3b inactivator of complement-mediated function in vivo in a patient with C3b inactivator deficiency.

Authors:  J B Ziegler; C A Alper; R S Rosen; P J Lachmann; L Sherington
Journal:  J Clin Invest       Date:  1975-03       Impact factor: 14.808

5.  Studies on the inhibition of C56-initiated lysis (reactive lysis). V. The roleof C567-INH in the regulation of complement-dependent haemolysis initiated by cobravenom factor.

Authors:  B McLeod; T F Lint; P Baker; C Behrends; H Gewurz
Journal:  Immunology       Date:  1975-04       Impact factor: 7.397

6.  C3b inactivator in the rheumatic diseases. Measurement by radial immunodiffusion and by inhibition of formation of properdin pathway C3 convertase.

Authors:  K Whaley; P H Schur; S Ruddy
Journal:  J Clin Invest       Date:  1976-06       Impact factor: 14.808

7.  Requirement of extracellular complement and immunoglobulin for intracellular killing of micro-organisms by human monocytes.

Authors:  P C Leijh; M T van den Barselaar; T L van Zwet; M R Daha; R van Furth
Journal:  J Clin Invest       Date:  1979-04       Impact factor: 14.808

8.  Identification of a 145,000 Mr membrane protein as the C3d receptor (CR2) of human B lymphocytes.

Authors:  J J Weis; T F Tedder; D T Fearon
Journal:  Proc Natl Acad Sci U S A       Date:  1984-02       Impact factor: 11.205

9.  Modulation of the formation of the human amplification C3 convertase of complement by polycations.

Authors:  F Maillet; M D Kazatchkine
Journal:  Immunology       Date:  1983-09       Impact factor: 7.397

10.  Activation of the alternative complement pathway by exposure of phosphatidylethanolamine and phosphatidylserine on erythrocytes from sickle cell disease patients.

Authors:  R H Wang; G Phillips; M E Medof; C Mold
Journal:  J Clin Invest       Date:  1993-09       Impact factor: 14.808
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.